Stryker Shares Slide 10% as Q3 Revenue, 2026 Guidance Miss Street Targets

Stryker Corp. (NYSE:SYK) reported Q3 revenue of $6.52B, missing estimates of $6.61B, and adjusted EPS of $3.52, below the $3.55 consensus. Shares fell 10.4% in pre-market trading. The company's 2026 guidance also fell short, with adjusted EPS projected at $14.80-$14.90, below the $14.95 consensus. CEO Kevin Lobo cited strong fundamentals but acknowledged the shortfall. Analysts lowered price targets but maintained Buy ratings.

Original reporting
Published Oct 30, 2026, 10:55 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 11:53 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$SYK
Bearish
high confidence
Mentioned
$SYK
Relevance
8/10
AlphAI data visualization · based on finance.biggo.com
Decision brief

The 30-second read

$SYKBearishHigh
01

Why it matters

The earnings miss and lowered guidance are likely to keep the stock under pressure, though the new buyback could provide a floor.

02

Market read

The report is a primary earnings disclosure for a large‑cap med‑tech company, driving immediate price action and sector sentiment.

03

What to watch

Strong 9.2% growth in MedSurg segment and a $3B additional buyback authorization may support longer‑term upside.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Stryker's Q3 results were released on Oct 30, 2026, with a notable 10% pre‑market decline.

Company-level read

Ticker impact

$SYKBearishHigh confidence
Context

Stryker reported Q3 revenue of $6.52B and EPS of $3.52, both missing consensus, and lowered 2026 EPS guidance to $14.80‑$14.90, triggering a 10% share drop.

Expected impact

downward pressure as the market prices in the revenue and guidance miss

Evidence & confidence

The miss on both top‑line and EPS, plus guidance below consensus, typically leads to further sell‑off beyond the initial 10% move.

Market effects

Medical‑technology sector may see broader weakness as peers are re‑rated on earnings expectations.

U.S. healthcare stocks could face short‑term pullback.

Limited to investors tracking large‑cap med‑tech names.

Counterpoint

If the market overreacts, the stock could rebound on the announced $4B buyback program.

Key entities

  • Kevin A. Lobo

    Chair and CEO of Stryker, quoted on performance and outlook.

Related articles

Low

Bulgaria accepts first five US M1126 Stryker ICV armored vehicles under $1.4 billion Army modernization.

Bulgaria has received the first five of 183 Stryker armored vehicles under a $1.4 billion modernization deal. The order includes various configurations, with deliveries delayed due to component shortages. General Dynamics Land Systems-Canada manufactures the vehicles, and TEREM-Ivaylo handles final assembly and testing. The project's cost has increased by 2.76% due to inflation and other factors.

$ZBHHighAI 9/10

Zimmer Biomet Soars 15% as Hip and Tech Growth Lifts Guidance, “Validating the Progress” of Its Strategy

Zimmer Biomet (ZBH) shares rose 15% after Q3 sales grew 3.7% in constant currency, with hips, sports medicine, and technology segments growing 7% or more. The company raised its 2026 guidance, citing progress in diversification. Knees, 37% of sales, declined 2.6%. Rival Stryker (SYK) and Smith & Nephew (SNN) also saw gains, despite Smith & Nephew cutting its outlook.